BrosMed and Cordis Partner to Promote the Next-Generation Drug-Coated Balloon VaSecure™ in China Market

On February 10, BrosMed and Cordis signed an exclusive distribution agreement for VaSecure™, BrosMed’s next-generation drug-coated peripheral balloon catheter, in the China market. Featuring globally pioneering technology, VaSecure™ is designed to achieve “zero drug loss” and support long-term drug retention, addressing three major challenges that have long affected peripheral drug-coated balloons: drug loss, drug transfer, and drug retention. This breakthrough represents an important step forward in the advancement of peripheral drug-coated balloon technology.

As a global company in cardiovascular and peripheral vascular intervention, Cordis will leverage its established commercial network in China to accelerate the commercialization of VaSecure™ following the signing of the exclusive distribution agreement. This partnership will also help Cordis further expand its peripheral interventional product portfolio and provide a wider range of localized solutions to medical professionals and patients in China.

Innovative Design

“Zero Drug Loss” Is Going to Be EPIC

Peripheral drug-coated balloons (DCBs) have been widely used in the treatment of peripheral arterial disease. Today, this field is entering a new stage of innovation.

After several years of dedicated research and development, BrosMed has developed the VaSecure™ Paclitaxel-Coated PTA Balloon Catheter, the world’s first drug-coated balloon catheter featuring a protective sheath throughout the entire delivery process, from sheath entry to arrival at the target lesion. Combined with BrosMed’s patented “Micro-needle-crystals” coating technology, VaSecure™ is designed to solve three major challenges associated with current peripheral DCBs: drug loss, drug transfer, and drug retention. It provides an innovative solution for the treatment of peripheral arterial disease.

The main challenges with current peripheral DCBs in clinical application include severe drug loss, low drug transfer efficiency, and short drug retention time at the target lesion. Due to the structural characteristics of DCBs, both hydrophilic and lipophilic excipients face challenges in preventing drug loss during balloon delivery and the subsequent washing effect caused by blood flow. Drug loss not only reduces effective drug transfer to the vessel wall, but may also increase the risk of distal embolization. In addition, low drug transfer efficiency and insufficient drug retention time at the target lesion may affect the stability of clinical outcomes.

VaSecure™ Paclitaxel-Coated PTA Balloon Catheter features an innovative delivery platform with a protective sheath covering the drug-coated balloon throughout the delivery process, from sheath entry to arrival at the target lesion. This design enables “zero drug loss” during delivery, helps reduce the risk of distal embolization, and enhances drug transfer efficiency to the vessel wall.

In addition, VaSecure™ applies a novel “Micro-needle-crystals” drug coating and patented spraying technology. Through a penetrative drug delivery mechanism, this design improves drug transfer efficiency and supports long-term drug retention in the vessel wall.

Superior product design supports strong clinical performance. Clinical trial data for VaSecure™ demonstrated promising results: late lumen loss (LLL) of the target lesion was 0.38 mm at six months after the procedure, and the target lesion revascularization (TLR) rate was 4% at six months.

VaSecure™ has been approved by the National Medical Products Administration (NMPA) in China and is indicated for percutaneous transluminal angioplasty in patients with stenotic or occlusive lesions of the superficial femoral artery (SFA) and proximal popliteal artery (PPA). VaSecure™ is also currently undergoing CE registration and is expected to enter international markets in the future.

Complementary Strengths and Win-Win Cooperation

As long-standing partners, BrosMed and Cordis are once again working together to support the commercialization of the VaSecure™ drug-coated peripheral balloon catheter.

Under the exclusive distribution agreement, Cordis will leverage its professional and well-established marketing network to support the introduction of the VaSecure™ Paclitaxel-Coated PTA Balloon Catheter in the China market.

At the same time, this agreement will further expand Cordis’ peripheral interventional product portfolio by adding a drug-coated treatment option for peripheral vascular interventions, creating new opportunities for business growth.

Looking ahead, BrosMed will continue to embrace open collaboration, combine global expertise with Chinese innovation, and work with partners to address unmet clinical needs while contributing to the advancement of vascular intervention worldwide.